{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001328786,0.001108205,0.001503154,0.0004513504,0.0002828637,0.0009330426,0.0007707187,0.0008464645,0.002722535],"category_scores_gemma":[0.0005228534,0.0005115482,0.001165504,0.0004731743,0.0006548289,0.0008557001,0.0002895689,0.003297861,0.0006489129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001053967,"about_ca_system_score_gemma":0.001147301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002016977,"about_ca_topic_score_gemma":0.007177122,"domain_scores_codex":[0.99972,0.00009777037,0.00001106926,0.00003859122,0.00004499649,0.00008745253],"domain_scores_gemma":[0.999779,0.00003684117,0.00004864445,0.00002256691,0.00001657908,0.00009637969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3465322,0.05756346,0.007303432,0.002536609,0.003319026,0.0004017234,0.0006457659,0.01098272,0.110586,0.001880587,0.01842643,0.439822],"study_design_scores_gemma":[0.6575285,0.277361,0.02091561,0.0001448392,0.001995438,0.0008720714,0.0001584245,0.00419146,0.01488315,0.0008734034,0.02096942,0.0001067991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806637,0.009637418,0.001119546,0.001075741,0.0002391138,0.00135406,0.001484361,0.0001696809,0.004256353],"genre_scores_gemma":[0.9705173,0.01276782,0.003419843,0.001877882,0.0001289267,0.001182322,0.003084548,0.00009019991,0.006931225],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002722535,"threshold_uncertainty_score":0.009107769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.2559041791176628,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}